

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 001-37569

**STRONGBRIDGE BIOPHARMA plc**

(Exact name of Registrant as specified in its charter)

**Ireland**  
(State or other jurisdiction of  
incorporation or organization)

**98-1275166**  
(I.R.S. Employer  
Identification Number)

**900 Northbrook Drive  
Suite 200**

**Trevose, PA 19053**

(Address of principal executive offices)

**Registrant's Telephone Number, Including Area Code: +1 610-254-9200**

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

<u>Title of each class:</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered:</u>
Ordinary shares, par value \$0.01 per share	SBBP	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and emerging growth company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	<input type="checkbox"/>	Accelerated Filer	<input checked="" type="checkbox"/>
Non-Accelerated Filer	<input type="checkbox"/>	Smaller Reporting Company	<input checked="" type="checkbox"/>
		Emerging Growth Company	<input checked="" type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of July 29, 2019, there were 54,186,268 ordinary shares of the registrant issued and outstanding.

---

---

**TABLE OF CONTENTS**

	<u>Page</u>
<b><u>PART I. Financial Information</u></b>	<b>1</b>
<b><u>Item 1. Financial Statements</u></b>	<b>1</b>
<u>Consolidated Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018</u>	1
<u>Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018 (unaudited)</u>	2
<u>Consolidated Statements of Stockholders' Equity (Deficit) (unaudited)</u>	3
<u>Consolidated Statements of Cash Flow for the Six Months Ended June 30, 2019 and 2018 (unaudited)</u>	4
<u>Notes to the Unaudited Consolidated Financial Statements</u>	5
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	<b>15</b>
<b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	<b>23</b>
<b><u>Item 4. Controls and Procedures</u></b>	<b>23</b>
<b><u>PART II. Other Information</u></b>	<b>24</b>
<b><u>Item 1. Legal Proceedings</u></b>	<b>24</b>
<b><u>Item 1A. Risk Factors</u></b>	<b>24</b>
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	<b>26</b>
<b><u>Item 3. Defaults Upon Senior Securities</u></b>	<b>26</b>
<b><u>Item 4. Mine Safety Disclosures</u></b>	<b>26</b>
<b><u>Item 5. Other Information</u></b>	<b>26</b>
<b><u>Item 6. Exhibits</u></b>	<b>26</b>
<b><u>SIGNATURES</u></b>	<b>27</b>

Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q (this "Quarterly Report") are referred to without the ® and ™ symbols, but absence of such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. The trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners.

---

**PART I – FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****STRONGBRIDGE BIOPHARMA plc****Consolidated Balance Sheets**  
**(In thousands, except share and per share data)**  
**(unaudited)**

	<u>June 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 86,167	\$ 122,490
Accounts receivable	6,343	1,626
Inventory	3,218	3,946
Prepaid expenses and other current assets	2,454	4,236
Total current assets	98,182	132,298
Property and equipment, net	291	294
Right of use assets, net	934	—
Intangible asset, net	27,621	30,132
Goodwill	7,256	7,256
Other assets	872	305
Total assets	<u>\$ 135,156</u>	<u>\$ 170,285</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,469	\$ 1,184
Accrued liabilities and other current liabilities	17,035	16,065
Total current liabilities	18,504	17,249
Warrant liability	8,636	15,513
Supply agreement liability, noncurrent	15,454	24,568
Other long-term liabilities	1,273	—
Total liabilities	43,867	57,330
Commitments and contingencies (Note 7)		
Stockholders' equity:		
Deferred shares, \$1.098 par value, 40,000 shares authorized, issued and outstanding at June 30, 2019 and December 31, 2018	44	44
Ordinary shares, \$0.01 par value, 600,000,000 shares authorized at June 30, 2019 and December 31, 2018; 54,186,268 and 54,122,074 shares issued and outstanding at June 30, 2019 and December 31, 2018	542	541
Additional paid-in capital	328,416	323,402
Accumulated deficit	(237,713)	(211,032)
Total stockholders' equity	91,289	112,955
Total liabilities and stockholders' equity	<u>\$ 135,156</u>	<u>\$ 170,285</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**STRONGBRIDGE BIOPHARMA plc**
**Consolidated Statements of Operations**  
(In thousands, except share and per share data)  
(unaudited)

	Three Months Ended June 30		Six Months Ended June 30	
	2019	2018	2019	2018
<b>Revenues:</b>				
Net product sales	\$ 6,073	\$ 4,296	\$ 10,406	\$ 8,166
Royalty revenues	6	—	16	—
Total revenues	<u>6,079</u>	<u>4,296</u>	<u>10,422</u>	<u>8,166</u>
<b>Cost and expenses:</b>				
Cost of sales (excluding amortization of intangible assets)	\$ 1,022	\$ 753	\$ 1,835	\$ 1,420
Selling, general and administrative	12,182	15,210	24,282	27,572
Research and development	8,739	5,453	15,322	10,334
Amortization of intangible assets	1,255	1,872	2,511	3,641
Total cost and expenses	<u>23,198</u>	<u>23,288</u>	<u>43,950</u>	<u>42,967</u>
Operating loss	(17,119)	(18,992)	(33,528)	(34,801)
<b>Other income, net:</b>				
Income from field services agreement	1,725	—	3,741	—
Expense from field services agreement	(1,758)	—	(3,987)	—
Unrealized gain on fair value of warrants	8,697	19,017	6,877	9,317
Interest expense	—	(3,289)	—	(6,163)
Loss on extinguishment of debt	—	—	—	(500)
Other income, net	608	342	1,293	502
Total other income, net	<u>9,272</u>	<u>16,070</u>	<u>7,924</u>	<u>3,156</u>
Loss before income taxes	(7,847)	(2,922)	(25,604)	(31,645)
Income tax expense	(400)	(1)	(1,077)	(1)
Net loss	<u>\$ (8,247)</u>	<u>\$ (2,923)</u>	<u>\$ (26,681)</u>	<u>\$ (31,646)</u>
<b>Net loss attributable to ordinary shareholders:</b>				
Basic	<u>\$ (8,247)</u>	<u>\$ (2,923)</u>	<u>\$ (26,681)</u>	<u>\$ (31,646)</u>
Diluted	<u>\$ (16,944)</u>	<u>\$ (21,940)</u>	<u>\$ (33,558)</u>	<u>\$ (40,963)</u>
<b>Net loss per share attributable to ordinary shareholders:</b>				
Basic	<u>\$ (0.15)</u>	<u>\$ (0.06)</u>	<u>\$ (0.49)</u>	<u>\$ (0.69)</u>
Diluted	<u>\$ (0.30)</u>	<u>\$ (0.43)</u>	<u>\$ (0.60)</u>	<u>\$ (0.81)</u>
<b>Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:</b>				
Basic	<u>54,175,731</u>	<u>45,829,600</u>	<u>54,165,439</u>	<u>45,728,793</u>
Diluted	<u>55,781,078</u>	<u>50,437,716</u>	<u>56,262,936</u>	<u>50,363,801</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**STRONGBRIDGE BIOPHARMA plc**

**Consolidated Statement of Stockholders' Equity (Deficit)**  
**(In thousands, except share amounts)**  
**(unaudited)**

	Ordinary Shares		Deferred Shares		Additional Paid-In Capital	Accumulated Deficit	Total Shareholders' (Deficit) Equity
	Shares	Amount	Shares	Amount			
Balance—March 31, 2018	45,531,827	\$ 455	40,000	\$ 44	\$ 272,960	\$ (271,606)	\$ 1,853
Net loss	—	—	—	—	—	(2,923)	(2,923)
Stock-based compensation	—	—	—	—	1,985	—	1,985
Ordinary shares issued, net of shares withheld for employee taxes	2,826	—	—	—	(13)	—	(13)
Exercise of stock options	2,838	*	—	—	—	—	*
Issuance of shares in connection with at-the-market facility, net of costs	1,172,557	12	—	—	7,949	—	7,961
Balance—June 30, 2018	<u>46,710,048</u>	<u>\$ 467</u>	<u>40,000</u>	<u>\$ 44</u>	<u>\$ 282,881</u>	<u>\$ (274,529)</u>	<u>\$ 8,863</u>
Balance—December 31, 2017	40,149,812	\$ 401	40,000	\$ 44	\$ 230,524	\$ (242,883)	\$ (11,914)
Net loss	—	—	—	—	—	(31,646)	(31,646)
Stock-based compensation	—	—	—	—	3,673	—	3,673
Issuance of shares, net of offering costs	5,255,683	53	—	—	33,455	—	33,508
Ordinary shares issued, net of shares withheld for employee taxes	91,989	1	—	—	(442)	—	(441)
Exercise of stock options	40,007	*	—	—	59	—	59
Issuance of shares in connection with at-the-market facility, net of costs	1,172,557	12	—	—	7,949	—	7,961
Issuance of warrants related to loan agreements	—	—	—	—	7,663	—	7,663
Balance—June 30, 2018	<u>46,710,048</u>	<u>\$ 467</u>	<u>40,000</u>	<u>\$ 44</u>	<u>\$ 282,881</u>	<u>\$ (274,529)</u>	<u>\$ 8,863</u>
Balance—March 31, 2019	54,167,948	\$ 542	40,000	\$ 44	\$ 325,863	\$ (229,466)	\$ 96,983
Net loss	—	—	—	—	—	(8,247)	(8,247)
Stock-based compensation	—	—	—	—	2,572	—	2,572
Exercise of stock options	4,113	*	—	—	12	—	12
Ordinary shares issued, net of shares withheld for employee taxes	14,207	*	—	—	(31)	—	(31)
Balance—June 30, 2019	<u>54,186,268</u>	<u>\$ 542</u>	<u>40,000</u>	<u>\$ 44</u>	<u>\$ 328,416</u>	<u>\$ (237,713)</u>	<u>\$ 91,289</u>
Balance—December 31, 2018	54,122,074	\$ 541	40,000	\$ 44	\$ 323,402	\$ (211,032)	\$ 112,955
Net loss	—	—	—	—	—	(26,681)	(26,681)
Stock-based compensation	—	—	—	—	4,895	—	4,895
Exercise of stock options	43,841	1	—	—	178	—	179
Ordinary shares issued, net of shares withheld for employee taxes	20,353	*	—	—	(59)	—	(59)
Balance—June 30, 2019	<u>54,186,268</u>	<u>\$ 542</u>	<u>40,000</u>	<u>\$ 44</u>	<u>\$ 328,416</u>	<u>\$ (237,713)</u>	<u>\$ 91,289</u>

\* Represents an amount less than \$1.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**STRONGBRIDGE BIOPHARMA plc**
**Consolidated Statements of Cash Flow  
(In thousands)  
(unaudited)**

	Six Months Ended June 30,	
	2019	2018
Cash flows from operating activities:		
Net loss	\$ (26,681)	\$ (31,646)
Adjustments to reconcile net loss to net cash used in operating activities:		
Change in fair value of warrant liability	(6,877)	(9,317)
Stock-based compensation	4,895	3,673
Amortization of intangible assets	2,511	3,641
Interest and related guarantee fees paid in kind	—	1,813
Amortization of debt discounts and debt issuance costs	—	697
Loss on extinguishment of debt	—	500
Depreciation	36	10
Changes in operating assets and liabilities:		
Accounts receivable	(4,717)	(792)
Inventory	393	(675)
Prepaid expenses and other current assets	1,782	(1,870)
Other assets	(1,166)	368
Accounts payable	285	1,164
Accrued liabilities and other liabilities	(6,872)	(114)
Net cash used in operating activities	<u>(36,411)</u>	<u>(32,548)</u>
Cash flows from investing activities:		
Payment for acquisitions	—	(24,655)
Purchases of property and equipment	(33)	(310)
Net cash used in investing activities	<u>(33)</u>	<u>(24,965)</u>
Cash flows from financing activities:		
Proceeds from long-term debt, net	—	44,930
Payment for loss on extinguishment of debt	—	(500)
Proceeds from issuance of ordinary shares, net	—	33,508
Proceeds from issuance of ordinary shares in connection with at-the-market offering	—	7,961
Proceeds from exercise of stock options	180	59
Payments related to tax withholding for net-share settled equity awards	(59)	(441)
Net cash provided by financing activities	<u>121</u>	<u>85,517</u>
Net (decrease) increase in cash and cash equivalents	(36,323)	28,004
Cash and cash equivalents—beginning of period	122,490	57,510
Cash and cash equivalents—end of period	\$ 86,167	\$ 85,514
Supplemental disclosures of cash flow information:		
Cash paid during the year for:		
Interest	<u>\$ —</u>	<u>\$ 3,501</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**STRONGBRIDGE BIOPHARMA plc**

**Notes to Unaudited Consolidated Financial Statements**

**1. Organization**

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (the “FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.

We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation, such as acromegaly. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”).

In January 2018, Strongbridge Ireland Ltd., one of our wholly-owned subsidiaries, acquired the U.S. and Canadian rights to Macrilen (macimorelin), the first and only oral drug approved by the FDA for the diagnosis of patients with adult growth hormone deficiency. We launched Macrilen in the United States in July 2018. In December 2018, we sold Strongbridge Ireland Ltd. to Novo Nordisk Healthcare AG (“Novo”) for \$145 million plus the right to receive tiered royalties on net sales of Macrilen through 2027. In addition, Strongbridge U.S. Inc, another of our wholly-owned subsidiaries, entered into an agreement with Novo Nordisk Inc., subsidiary of Novo (“NNI”), pursuant to which NNI will fund the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years.

***Liquidity***

We believe that our cash resources of \$86.2 million at June 30, 2019 will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of these unaudited consolidated financial statements.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We plan to continue to fund our operations and capital funding needs through equity or debt financing along with revenues from Keveyis and royalty revenues from Macrilen. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

**2. Summary of significant accounting policies and basis of presentation**

***Basis of presentation***

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements. Actual results could differ from those estimates. Results for the six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission on February 27, 2019 (the “2018 Annual Report”). Our significant accounting policies are described in Note 2 of the notes to the audited consolidated financial statements included in our 2018 Annual Report. Since the date of those financial statements, there have been no changes to our significant accounting policies.

### **Royalty Revenues**

Royalty revenues are from commercial sales of Macrilen by Novo Nordisk Healthcare AG, based on net sales.

### **Leases**

We account for leases in accordance with Accounting Standards Codification Topic 842, *Leases*, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (*i.e.*, property, plant, and equipment), and (2) we have the right to control the use of the identified asset.

Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date.

Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments

The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all our other leases.

We adopted ASC 842 using a modified retrospective transition approach as of the effective date, as permitted by the amendments in ASU 2018-11. As a result, we were not required to adjust our comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption (*i.e.*, January 1, 2019). We have elected to adopt the package of transition practical expedients and, therefore, have not reassessed (1) whether existing or expired contracts contain a lease, (2) lease classification for existing or expired leases or (3) the accounting for initial direct costs that were previously capitalized. We did not elect the practical expedient to use hindsight for leases existing at the adoption date. Further, we do not expect the amendments in ASU 2018-01: Land Easement Practical Expedient to have an effect on us because we do not enter into land easement arrangements.

#### ***Income and Expense from Field Services Agreement***

For our field services agreement with NNI, our income and expense are being recorded as non-operating income and expense, respectively.

#### ***Segment information***

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment.

#### ***Net loss per share***

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted-average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti-dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units (“RSUs”) and equity-classified warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2019 and 2018, as they would be anti-dilutive:

	<u>June 30,</u>	
	<u>2019</u>	<u>2018</u>
Warrants	1,803,253	1,803,253
Stock options issued and outstanding	10,241,158	8,661,560
Unvested RSUs	964,850	173,400

#### ***Recent accounting pronouncements – not yet adopted***

In January 2017, the FASB issued ASU 2017-04, *Intangibles - Goodwill and Other: Simplifying the Accounting for Goodwill Impairment*. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for us beginning in the first quarter of fiscal year 2020, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect any impact from this standard.

### 3. Revenue recognition

#### *Product sales, net*

We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, most of whom are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of the product to the Customer. Transfer of control occurs upon receipt of the product by the Customer. We expense incremental costs related to the set-up of contracts with the Customer when incurred, as these costs do not meet the criteria for capitalization.

#### *Reserves for variable consideration*

Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

*Trade Discount:* We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

*Funded Co-pay Assistance Program:* We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the Customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

*Government Rebates:* We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare

coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that have been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

*Temporary Supply and Patient Assistance Programs:* We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while there is a determination of the patient's third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to uninsured patients who satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

#### **Royalty Revenues**

Royalty revenues are from commercial sales of Macrilen by Novo, based on net sales.

#### **4. Fair value measurement**

We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

The guidance requires fair value measurements to maximize the use of "observable inputs." The three-level hierarchy of inputs to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (*i.e.*, supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement.

We did not have any transfers between the different levels.

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):

	As of June 30, 2019			Total
	Level I	Level II	Level III	
Cash equivalents	85,759	—	—	85,759
Total assets	\$ 85,759	\$ —	\$ —	\$ 85,759
Warrant liability	—	—	8,636	8,636
Total liabilities	\$ —	\$ —	\$ 8,636	\$ 8,636

  

	As of December 31, 2018			Total
	Level I	Level II	Level III	
Cash equivalents	122,300	—	—	122,300
Total assets	\$ 122,300	\$ —	\$ —	\$ 122,300
Warrant liability	—	—	15,513	15,513
Total liabilities	\$ —	\$ —	\$ 15,513	\$ 15,513

The following table presents a reconciliation of our level 3 Warrant liability (in thousands):

	As of June 30, 2019
Balance as of December 31, 2018	\$ 15,513
Unrealized gain on fair value of warrants for the six months ended June 30, 2019	(6,877)
Balance as of June 30, 2019	\$ 8,636

## 5. Intangible assets and goodwill

The following represents the balance of our intangible assets as follows (in thousands):

	As of June 30, 2019		
	Beginning of Period	Amortization	End of Period
Keveyis	\$ 30,132	\$ (2,511)	\$ 27,621
Goodwill	7,256	—	7,256
Total	\$ 37,388	\$ (2,511)	\$ 34,877

Our finite lived intangible assets consist of acquired developed product rights obtained from our acquisition of Keveyis (dichlorophenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).

Pursuant to the terms of the Asset Purchase Agreement and Supply Agreement that we entered into with Taro in December 2016, we paid Taro an upfront payment in two installments of \$1 million in December 2016 and \$7.5 million in March 2017. We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at \$29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability will be reduced as we purchase inventory over the term of the Supply Agreement that we entered into with Taro in December 2016. In addition, we incurred transaction costs of \$2.4 million. The overall recording of the transaction resulted in the recording of an intangible asset of \$40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of \$1.3 million and \$2.5 million for the three and six months ended June 30, 2019, respectively, compared to \$1.9 million and \$3.6 million for the three and six months ended June 30, 2018, respectively.

## 6. Accrued liabilities and other current liabilities

Accrued liabilities and other current liabilities consist of the following (in thousands):

	June 30,	December 31,
	2019	2018
Supply agreement - current portion	\$ 5,375	\$ 1,638
Consulting and professional fees	4,077	4,145
Employee compensation	2,816	5,717
Accrued sales allowances	1,863	2,233
Accrued taxes	1,596	535
Accrued royalties	577	802
Lease liability - current portion	330	—
Other	401	995
Total accrued liabilities	<u>\$ 17,035</u>	<u>\$ 16,065</u>

## 7. Commitments and contingencies

### (a) Commitments to Taro Pharmaceuticals Industries Ltd.

In December 2016, we acquired the U.S. marketing rights to Keveyis (dichlorphenamide) from Taro. Under the terms of an Asset Purchase Agreement, we paid Taro an upfront payment in two installments of \$1 million in December 2016 and \$7.5 million in March 2017, and will pay an aggregate of \$7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately \$29 million over a six-year period. As of June 30, 2019, our remaining obligation was \$22.1 million. Our Supply Agreement with Taro may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. We are also required to reimburse Taro for their royalty obligation resulting from their sale of Keveyis to us.

### (b) Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction, such as breaches of contracts, unfavorable tax consequences and employee liabilities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss and such amount could be material to our financial statements. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall maximum amount of the obligation under such indemnifications cannot be reasonably estimated. However, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable at this time.

## 8. Leases

We lease office space under operating leases. Our leases have initial lease terms ranging from one to five years. Our lease agreements contain provisions for future rent increases.

As of June 30, 2019, future minimum commitments under facility operating leases were as follows (in thousands):

	<u>Operating leases</u>
2019	207
2020	470
2021	481
2022	492
2023	207
Total minimum lease payments	<u>\$ 1,857</u>

The components of lease cost for the quarter ended June 30, 2019 are as follows (in thousands):

	<u>Six Months Ended June 30, 2019</u>
<b>Lease costs</b>	
Amortization of right of use assets	\$ 221
Interest on lease liabilities	64
Total lease cost	<u>\$ 285</u>

Amounts reported in the Consolidated Balance Sheets for leases where we are the lessee as of June 30, 2019 were as follows (in thousands):

	<u>June 30, 2019</u>
<b>Operating Leases</b>	
Right of use asset	\$ 934
Lease liability	\$ 1,603
<b>Remaining lease term</b>	
Operating leases	4 years
<b>Discount rate</b>	
Operating leases	7.69%

## 9. Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized.

We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed.

We recorded income tax expense of \$1.1 million for the six months ended June 30, 2019 and \$0.4 million for the three months ended June 30, 2019, as a result of tax liability expected in connection with the intercompany transfer of intellectual property.

The global intangible low-taxed income tax and base erosion provisions are effective for taxable years beginning after December 31, 2017. We do not currently expect these provisions to have a material impact on our tax rate as we do not own any controlled foreign corporations and they are currently below the gross receipts threshold for purposes of the base erosion provisions.

## 10. Warrants

### Warrants

Our outstanding warrants as of June 30, 2019 are as follows:

	Classification	Exercise Price	Expiration Date	Warrants Issued	Warrants Exercised	Warrants Outstanding June 30, 2019
Warrants in connection with private equity placement	Liability	\$ 2.50	6/28/2022	7,000,000	(1,970,000)	5,030,000
Warrants in connection with Horizon and Oxford loan agreement	Equity	\$ 2.45	12/28/2026	428,571	(267,857)	160,714
Warrants in connection with CRG loan agreement	Equity	\$ 7.37	7/14/2024	394,289	—	394,289
Warrants in connection with CRG loan amendment in January 2018	Equity	\$ 10.00	1/16/2025	1,248,250	—	1,248,250
				<u>9,071,110</u>		<u>6,833,253</u>

## 11. Stock-based compensation

Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan became effective on February 23, 2017. As of June 30, 2019, 688,887 shares are available for issuance pursuant to the Inducement Plan.

Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporation’s employees, and for the grant of nonstatutory stock options, stock awards, and RSUs to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan became effective on September 3, 2015. As of June 30, 2019, 274,542 shares are available for issuance pursuant to the 2015 Plan.

Our board of directors has adopted, and our shareholders have approved, the Non-Employee Director Equity Compensation Plan (the “Non-Employee Director Plan”). The Non-Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and RSUs to our non-employee directors. The Non-Employee Director Plan became effective on September 3, 2015. As of June 30, 2019, 32,151 shares are available for issuance pursuant to the Non-Employee Director Plan.

A summary of our outstanding stock options as of June 30, 2019 is as follows:

	Options Outstanding			
	Number of Shares	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding—January 1, 2019	8,579,511	\$ 7.35	7.57	\$ 3,281
Granted	1,989,900	\$ 4.52		
Forfeited and cancelled	(284,412)	\$ 6.07		
Exercised	(43,841)	\$ 4.12		
Outstanding—June 30, 2019	<u>10,241,158</u>	\$ 6.85	7.55	\$ 469
Vested and exercisable—June 30, 2019	<u>5,004,978</u>	\$ 8.31	6.39	\$ 224

### Stock-based compensation expense

We recognized stock-based compensation expense for employees and directors for stock options and RSUs as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
Selling, general and administrative	\$ 1,966	\$ 1,521	\$ 3,764	\$ 2,801
Research and development	606	464	1,131	872
Total stock-based compensation	<u>\$ 2,572</u>	<u>\$ 1,985</u>	<u>\$ 4,895</u>	<u>\$ 3,673</u>

As of June 30, 2019, the total unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, is \$16.9 million, which we expect to recognize over an estimated weighted-average period of 2.82 years.

In determining the estimated fair value of our service-based awards, we use the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:

	Six Months Ended June 30,	
	2019	2018
Expected term (in years)	6.10	6.12
Risk-free interest rate	1.98% - 2.61%	2.25% - 2.96%
Expected volatility	78.70% - 80.85%	78.19% - 85%
Dividend rate	—%	—%

### Restricted stock units

Our board of directors have approved grants of RSUs to employees. These RSUs vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. All RSUs will fully vest upon a change of control of our company. If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the executive's tax withholding obligations. The RSUs will cease to be outstanding upon such issuance of ordinary shares. We recorded expense, which is included in the stock-based compensation table above, of \$533,000 and \$115,000 for the three months ended June 30, 2019 and 2018, respectively, and \$771,000 and \$264,000

for the six months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, the total unrecognized compensation expense related to unvested RSUs is \$3.2 million, which we expect to recognize over an estimated weighted-average period of 1.4 years.

A summary of our unvested RSUs as of June 30, 2019 is as follows:

	Number of Shares
Outstanding—January 1, 2019	143,100
Granted	891,000
Forfeited	(32,250)
Vested	(37,000)
Unvested—June 30, 2019	964,850

## ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The following discussion and analysis should be read in conjunction with our interim unaudited consolidated financial statements and related notes for the three and six months ended June 30, 2019 included elsewhere in this Quarterly Report on 10-Q (this “Quarterly Report”) and the audited financial statements and related notes for the year ended December 31, 2018 and related Management’s Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on February 27, 2019. As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “Strongbridge” refer to Strongbridge Biopharma plc.*

### Special Note Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, prospective products, size or market or patient population, plans, objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this Quarterly Report speaks only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of

this Quarterly Report except as required by law. You should also read carefully the factors described in the “Risk Factors” section of our 2018 Annual Report and this Quarterly Report to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements.

## Overview

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (“FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.

We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation, such as acromegaly. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”).

In January 2018, Strongbridge Ireland Ltd., one of our wholly-owned subsidiaries, acquired the U.S. and Canadian rights to Macrilen (macimorelin), the first and only oral drug approved by the FDA for the diagnosis of patients with adult growth hormone deficiency. We launched Macrilen in the United States in July 2018. In December 2018, we sold Strongbridge Ireland Ltd. to Novo Nordisk Healthcare AG (“Novo”) for \$145 million plus the right to receive tiered royalties on net sales of Macrilen through 2027. In addition, Strongbridge U.S. Inc, another of our wholly-owned subsidiaries, entered into an agreement with Novo Nordisk Inc., subsidiary of Novo (“NNI”), pursuant to which NNI will fund the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years.

We are building a rare disease, franchise-based business model focused on expansion through a disciplined in-licensing and acquisition strategy. We will continue to identify and evaluate the acquisition of products and product candidates for licensing or acquisition that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise.

In December 2017, we received letters from the offices of U. S. Senators Amy Klobuchar, Susan Collins and Tammy Baldwin, and Senator Claire McCaskill, Ranking Member of the Homeland Security and Governmental Affairs Committee, that requested information relating to the marketing and sales of Keveyis principally relating to the pricing of Keveyis. We have cooperated with these voluntary requests for information, as well as additional follow-up requests in 2018.

## Recent Developments

In March 2019, we conducted a Type C meeting with the Division of Metabolic and Endocrine Products (DMEP) of the FDA. DMEP stated in its meeting minutes that the FDA generally requests that a sponsor conduct two adequate and well-controlled clinical studies for the proposed indication of a drug candidate under 21 CFR 314.126(b)(2). DMEP also noted that the FDA recognizes situations when a single trial may be sufficient. DMEP reiterated that the characteristics of an “adequate and well-controlled” investigation under 21 CFR 314.126 include the use of a control group (*e.g.*, placebo concurrent control, dose-comparison concurrent control), randomization and evaluation of primary endpoints that directly measure clinical benefits, or supported by evidence of clinical benefit. For this reason, while DMEP indicated that it would consider, as a review issue, the adequacy of a New Drug Application (NDA) submission with data from the SONICS trial as the sole Phase 3 evidence supporting the efficacy of RECORLEV, DMEP nonetheless recommended that we complete the LOGICS trial (which is double-blinded, randomized and placebo-controlled) and include the results from the LOGICS trial in addition to data from the SONICS trial in our NDA submission. We currently expect to receive LOGICS top-line data at the end of the first quarter of 2020

and, if supported by the data, submit an NDA for Recorlev in the third quarter of 2020 that will include data from each of the SONICS and LOGICS trials. In addition, the DMEP stated in its meeting minutes that our clinical pharmacology program for Recorlev, as described to them, appears reasonable to support an NDA filing for Recorlev provided that the data generated are found to be suitable.

### **Financial Operations Overview**

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

#### ***Net Product Sales***

Revenues from sales of our products are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered by us and the patients' payors. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a current liability (if the amount is payable to a party other than our customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue recognition" to our consolidated financial statements.

#### ***Royalty Revenues***

Royalty revenues are from commercial sales of Macrilen by Novo, based on net sales.

#### ***Cost of Sales***

Cost of sales includes third-party acquisition costs, third-party warehousing and product distribution charges.

#### ***Selling, General and Administrative Expenses***

Selling, general and administrative expenses include personnel costs, costs for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, travel and stock-based compensation. Outside professional services consist of legal, accounting and audit services, commercial evaluation and strategy services, sales, marketing and other consulting services.

#### ***Research and Development Expenses***

Our research and development expenses consist primarily of costs incurred in connection with the development of our product candidates, including:

- personnel-related costs, such as salaries, bonuses, benefits, travel and other related expenses, including stock-based compensation;
- expenses incurred under our agreements with contract research organizations, clinical sites, contract laboratories, medical institutions and consultants that plan and conduct our preclinical studies and clinical trials, including, in the case of consultants, stock-based compensation;
- costs associated with regulatory filings;
- upfront and milestone payments under in-license or acquisition agreements with third parties;

- costs of acquiring preclinical study and clinical trial materials, and costs associated with formulation and process development; and
- depreciation, maintenance and other facility-related expenses.

We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses as we progress our product candidates into and through clinical trials. Product candidates in later stages of clinical development generally have higher research and development costs than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We recognize costs for each grant project, preclinical study or clinical trial that we conduct based on our evaluation of the progress to completion, including the use of information and data provided to us by clinical sites and our external research and development vendors.

We expect our research and development expenses to increase in absolute dollars in the future as we continue to in-license or acquire product candidates and as we advance our existing and any future product candidates into and through clinical trials and pursue regulatory approval to market our product candidates. The process of conducting the necessary clinical research to obtain regulatory marketing approval of a product candidate is costly and time consuming. The probability that any of our product candidates receives regulatory marketing approval and eventually is able to generate revenue depends on a variety of factors, including the quality of our product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability. As a result of these uncertainties, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates, if approved. We may never succeed in achieving regulatory approval for any of our product candidates.

We do not allocate personnel-related research and development costs, including stock-based compensation or other indirect costs, to specific programs, as they are deployed across multiple projects under development.

#### ***Amortization of Intangible Assets***

Amortization of intangible assets relates to the amortization of our product rights to Keveyis. This intangible asset is being amortized over an eight-year period using the straight-line method.

#### ***Other Income, Net***

Other income, net, consists of unrealized loss on the remeasurement of the fair value of warrant liability, interest income generated from our cash and cash equivalents, foreign exchange gains, losses and gains and losses on investments. We record income and expenses relating to NNI service agreement to fund the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years beginning December 2018.

#### **Critical Accounting Policies and Significant Judgments and Estimates**

This management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe there have been no significant changes in our critical accounting policies and significant judgments and estimates as discussed in "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our 2018 Annual Report.

## Results of Operations

### Comparison of the Three and Six Months Ended June 30, 2019 and 2018.

The following table sets forth our results of operations for the three and six months ended June 30, 2019 and 2018.

	Three Months Ended June 30,			Six Months Ended June 30,		
	2019	2018	Change \$	2019	2018	Change \$
	(in thousands)			(in thousands)		
<b>Revenues:</b>						
Net product sales	\$ 6,073	\$ 4,296	\$ 1,777	\$ 10,406	\$ 8,166	\$ 2,240
Royalty revenues	6	—	6	16	—	16
Total revenues	<u>6,079</u>	<u>4,296</u>	<u>1,783</u>	<u>10,422</u>	<u>8,166</u>	<u>2,256</u>
<b>Cost and operating expenses:</b>						
Cost of sales (excluding amortization of intangible assets)	\$ 1,022	\$ 753	\$ 269	\$ 1,835	\$ 1,420	\$ 415
Selling, general and administrative	12,182	15,210	(3,028)	24,282	27,572	(3,290)
Research and development	8,739	5,453	3,286	15,322	10,334	4,988
Amortization of intangible assets	1,255	1,872	(617)	2,511	3,641	(1,130)
Total cost and expenses	<u>23,198</u>	<u>23,288</u>	<u>(90)</u>	<u>43,950</u>	<u>42,967</u>	<u>983</u>
Operating loss	(17,119)	(18,992)	1,873	(33,528)	(34,801)	1,273
Other income, net	9,272	16,070	(6,798)	7,924	3,156	4,768
Loss before income taxes	(7,847)	(2,922)	(4,925)	(25,604)	(31,645)	6,041
Income tax expense	(400)	(1)	(399)	(1,077)	(1)	(1,076)
Net loss	<u>\$ (8,247)</u>	<u>\$ (2,923)</u>	<u>\$ (5,324)</u>	<u>\$ (26,681)</u>	<u>\$ (31,646)</u>	<u>\$ 4,965</u>

### Revenues and Cost of Sales

Net revenue was \$6.1 million and cost of sales were \$1.0 million for the three months ended June 30, 2019, an increase of \$1.8 million and \$0.3 million, respectively, compared to the three months ended June 30, 2018. The increase was due to the continued sales growth of Keveyis, which was launched in April 2017.

Net revenue was \$10.4 million and cost of sales were \$1.8 million for the six months ended June 30, 2019, an increase of \$2.2 million and \$0.4 million, respectively, compared to the six months ended June 30, 2018. The increase is was to the continued sales growth of Keveyis, which was launched in April 2017.

### Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses during the three and six months ended June 30, 2019 and 2018:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2019	2018	Change \$	2019	2018	Change \$
	(in thousands)			(in thousands)		
Compensation and other personnel costs	\$ 6,133	\$ 6,443	\$ (310)	\$ 11,996	\$ 12,015	\$ (19)
Outside professional and consulting services	3,841	7,039	(3,198)	8,001	12,280	(4,279)
Stock-based compensation expense	1,981	1,521	460	3,792	2,801	991
Facility costs	227	207	20	493	476	17
Total selling, general and administrative expenses	<u>\$ 12,182</u>	<u>\$ 15,210</u>	<u>\$ (3,028)</u>	<u>\$ 24,282</u>	<u>\$ 27,572</u>	<u>\$ (3,290)</u>

Selling, general and administrative expenses were \$12.2 million for the three months ended June 30, 2019, a decrease of \$3.0 million compared to the three months ended June 30, 2018. Outside professional and consulting services decreased \$3.2 million during the three months ended June 30, 2019, primarily due to Macrilen launch preparation activities during the three months ended June 30, 2018 in connection with the launch of Macrilen in July 2018.

Selling, general and administrative expenses were \$24.3 million for the six months ended June 30, 2019, a decrease of \$3.3 million compared to the six months ended June 30, 2018. Outside professional and consulting services decreased \$4.3 million during the six months ended June 30, 2019, primarily due to Macrilen pre-launch preparation activities in the first half of 2018.

### Research and Development Expenses

The following table summarizes our research and development expenses during the three and six months ended June 30, 2019 and 2018:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2019	2018	Change \$	2019	2018	Change \$
	(in thousands)			(in thousands)		
Product development and supporting activities	\$ 6,652	\$ 3,828	\$ 2,824	\$ 11,387	\$ 7,051	\$ 4,336
Compensation and other personnel costs	1,495	1,162	333	2,831	2,412	419
Stock-based compensation expense	592	463	129	1,104	871	233
Total research and development expenses	<u>\$ 8,739</u>	<u>\$ 5,453</u>	<u>\$ 3,286</u>	<u>\$ 15,322</u>	<u>\$ 10,334</u>	<u>\$ 4,988</u>

Research and development expenses were \$8.7 million for the three months ended June 30, 2019, an increase of \$3.3 million compared to the three months ended June 30, 2018. The \$2.8 million increase in expenses for product development and supporting activities was primarily due to additional clinical development expenses for Recorlev.

Research and development expenses were \$15.3 million for the six months ended June 30, 2019, an increase of \$5.0 million compared to the six months ended June 30, 2018. The \$4.3 million increase in expenses for product development and supporting activities was primarily due to additional clinical development expenses for Recorlev.

*Amortization of Intangible Assets*

Amortization of intangible assets was \$1.3 million and \$2.5 million for the three and six months ended June 30, 2019, respectively, a decrease of \$0.6 million and \$1.1 million respectively, due to the prior year including amortization the intangible asset related to Macrilen, the rights to which we sold in December 2018.

*Other Income, Net*

The following table summarizes our other income, net, during the three and six months ended June 30, 2019 and 2018:

	Three Months Ended			Six Months Ended		
	June 30,		Change	June 30,		Change
	2019	2018	\$	2019	2018	\$
	(in thousands)			(in thousands)		
Income from field services agreement	\$ 1,725	\$ —	\$ 1,725	\$ 3,741	\$ —	\$ 3,741
Expense from field services agreement	(1,758)	—	(1,758)	(3,987)	—	(3,987)
Unrealized gain on fair value of warrants	8,697	19,017	(10,320)	6,877	9,317	(2,440)
Interest expense	—	(3,289)	3,289	—	(6,163)	6,163
Loss on extinguishment of debt	—	—	—	—	(500)	500
Other income, net	608	342	266	1,293	502	791
<b>Total other income, net</b>	<b>\$ 9,272</b>	<b>\$ 16,070</b>	<b>\$ (6,798)</b>	<b>\$ 7,924</b>	<b>\$ 3,156</b>	<b>\$ 4,768</b>

Other income, net, decreased by \$6.8 million for the three months ended June 30, 2019 as compared to the three months ended June 30, 2018. The decrease was primarily due to a \$10.3 million change in the unrealized gain on the fair value of our warrant liability in 2019, offset in part by a \$3.3 million change in interest expense in 2019. In addition, during 2019, we incurred \$1.8 million of expenses relating to our field-based service agreement with NNI and recorded \$1.7 million of related income.

Other income, net, increased by \$4.8 million for the six months ended June 30, 2019 as compared to the six months ended June 30, 2018. The increase was primarily due to a \$6.2 million decrease in interest expense, offset in part by a \$2.4 million change in the unrealized gain on the fair value of our warrant liability in 2019. In addition, we incurred \$4.0 million of expenses relating to our field based service agreement with NNI and recorded \$3.7 million of related income.

### Income Tax

We recorded income tax expense of \$1.1 million for the six months ended June 30, 2019 and \$0.4 million for the three months ended June 30, 2019, as a result of tax liability expected in connection with the intercompany transfer of intellectual property.

### Cash Flows

#### Comparison for the Six Months Ended June 30, 2019 and 2018:

	Six Months Ended June 30	
	2019	2018
	(in thousands)	
Net cash (used in) provided by:		
Operating activities	\$ (36,411)	\$ (32,548)
Investing activities	(33)	(24,965)
Financing activities	121	85,517
Net (decrease) increase in cash and cash equivalents	<u>\$ (36,323)</u>	<u>\$ 28,004</u>

#### Operating Activities

Net cash used in operating activities was \$36.4 million for the six months ended June 30, 2019 compared to \$32.5 million for the six months ended June 30, 2018.

#### Investing Activities

The decrease in net cash used in investing activities resulted from the \$24.7 million payment made to Aeterna Zentaris GmbH in 2018 for our acquisition of Macrilen and other expenses incurred with the acquisition.

#### Financing Activities

The decrease in net cash provided by financing activities resulted primarily from our receipt of \$44.4 million in proceeds from the amendment to our senior credit facility with CRG Servicing LLC ("CRG") and \$41.1 million in proceeds from our issuance of ordinary shares for the six months ended June 30, 2018.

### Liquidity and Capital Resources

We believe that our cash resources of \$86.2 million at June 30, 2019 will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of these financial statements.

Cash used to fund operating expenses is affected by the timing of when we are invoiced by our vendors, as reflected in the change in our outstanding accounts payable and accrued expenses set forth in the financial statements, included in this Quarterly Report.

Our future funding requirements will depend on many factors, including the following:

- the amount of revenue that we receive from sales of Keveyis and royalty revenues from Macrilen;
- the cost and timing of establishing sales, marketing, distribution and administrative capabilities;
- the scope, rate of progress, results and cost of our clinical trials testing and other related activities for Recorlev and veldoreotide;

- the number and characteristics of product candidates that we pursue, including any additional product candidates we may in-license or acquire;
- the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
- the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;
- the cost, timing and outcomes of regulatory approvals;
- the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder; and
- the emergence of competing technologies and their achieving commercial success before we do or other adverse market developments.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We plan to continue to fund our operations and capital funding needs through equity or debt financing along with revenues from Keveyis and royalty revenues from Macrilen. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

#### **Off-Balance Sheet Arrangements**

We do not have variable interests in variable interest entities or any off-balance sheet arrangements.

#### **ITEM 3. Quantitative and Qualitative Disclosures about Market Risk**

There have been no material changes to our market risk exposures since December 31, 2018.

#### **ITEM 4. Controls and Procedures**

##### ***Evaluation of Disclosure Controls and Procedures***

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2019, the end of the period covered by this Quarterly Report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of June 30, 2019 were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### **Changes in Internal Control over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II – OTHER INFORMATION**

### **ITEM 1. Legal Proceedings**

The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters.

### **ITEM 1A. Risk Factors**

The risks described in Item 1A. Risk Factors of our 2018 Annual Report could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in our 2018 Annual Report do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. The following is an update to our risk factors.

***The regulatory approval process of the FDA, EMA or any comparable foreign regulatory agency may be lengthy, time consuming and unpredictable.***

We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. The FDA, EMA and other comparable foreign regulatory agencies have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any comparable foreign regulatory agency. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the product candidates.

Furthermore, while certain of our employees have prior experience with submitting marketing applications to the FDA, EMA and comparable foreign regulatory agencies, we, as a company, have not submitted such applications for our product candidates. Applications for any of our product candidates could fail to receive regulatory approval for many reasons, including, but not limited to, the following:

- the FDA, EMA or any comparable foreign regulatory agency may disagree with the design or implementation of our clinical trials or our interpretation of data from nonclinical trials or clinical trials;
- the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval, including reliance on foreign clinical data;
- the data collected from clinical trials of our product candidates may not be sufficient to support a finding that has statistical significance or clinical meaningfulness or support the submission of an NDA or other submission, or to obtain regulatory approval in the United States or elsewhere;
- we may be unable to demonstrate to the FDA, EMA or any comparable foreign regulatory agency that a product candidate's risk-benefit ratio for its proposed indication is acceptable;

- the FDA, EMA or any comparable foreign regulatory agency may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
- the approval policies or regulations of the FDA, EMA or any comparable foreign regulatory agency may significantly change in a manner rendering our clinical data insufficient for approval.

In communications we had with the FDA, they recommended use of a concurrent control group in our SONICS Phase 3 clinical trial. However, SONICS utilizes an open-label, single-arm design because use of a placebo control in a parallel-arm monotherapy design was considered unethical or infeasible to enroll, depending on the specific country or clinical trial site under consideration. Studies lacking an active control group are more likely to be subject to unanticipated variability in study results that can potentially lead to flawed conclusions because they do not allow for discrimination of patient outcomes. In August 2018, we announced statistically significant positive top-line results from our SONICS Phase 3 clinical trial. However, even if we achieve the clinical trial's endpoints for this clinical trial, the FDA or other regulatory authorities could view our study results as potentially biased due to our lack of an active control group.

Our LOGICS study, which is a second Phase 3 clinical trial of Recorlev for the treatment of endogenous Cushing's syndrome, will supplement the long-term efficacy and safety data from the ongoing SONICS trial via a double-blind, placebo-controlled, randomized-withdrawal design that will randomize approximately 54 patients. The addition of a concurrent control group in LOGICS is an attempt to address FDA's request for such a control group that was lacking in SONICS. There can be no assurances, however, that the FDA or other regulatory authorities will view the LOGICS study results as sufficient.

In March 2019, we conducted a Type C meeting with the Division of Metabolic and Endocrine Products (DMEP) of the FDA. DMEP stated in its meeting minutes that the FDA generally requests that a sponsor conduct two adequate and well-controlled clinical studies for the proposed indication of a drug candidate under 21 CFR 314.126(b)(2). DMEP also noted that the FDA recognizes situations when a single trial may be sufficient. DMEP reiterated that the characteristics of an "adequate and well-controlled" investigation under 21 CFR 314.126 include the use of a control group (e.g., placebo concurrent control, dose-comparison concurrent control), randomization and evaluation of primary endpoints that directly measure clinical benefits, or supported by evidence of clinical benefit. For this reason, while DMEP indicated that it would consider, as a review issue, the adequacy of an NDA submission with data from the SONICS trial as the sole Phase 3 evidence supporting the efficacy of RECORLEV, DMEP nonetheless recommended that we complete the LOGICS trial (which is double-blinded, randomized and placebo-controlled) and include the results from the LOGICS trial in addition to data from the SONICS trial in our NDA submission. We currently expect to receive LOGICS top-line data at the end of the first quarter of 2020 and, if supported by the data, submit an NDA for Recorlev in the third quarter of 2020 that will include data from each of the SONICS and LOGICS trials. In addition, the DMEP stated in its meeting minutes that our clinical pharmacology program for Recorlev, as described to them, appears reasonable to support an NDA filing for Recorlev provided that the data generated are found to be suitable.

In addition, following FDA consultation, we have determined that the 505(b)(2) approval pathway, which permits an NDA applicant to rely on data from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference, is the appropriate pathway for a Recorlev NDA. We intend to rely on published literature and the FDA's prior findings concerning the safety and/or effectiveness of ketoconazole in our NDA for Recorlev and on similar processes in other jurisdictions. There can be no assurances, however, that the 505(b)(2) approval pathway in the United States, or similar approval pathways outside of the United States, will be available for Recorlev or that the FDA or other regulatory authorities will approve Recorlev through an application based on such pathways.

We generally plan to seek regulatory approval to commercialize our product candidates in the United States, the European Union and other key global markets. To obtain regulatory approval in other countries, we must comply with regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. Even if we are successful in

obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. Failure to obtain marketing authorization for our product candidates in any jurisdiction will result in our being unable to market and sell such products. Similarly, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.

Any of our current or future product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain regulatory approval. This could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of our product candidates.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None

**ITEM 3. Defaults Upon Senior Securities**

None.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

**ITEM 5. Other Information**

None.

**ITEM 6. Exhibits**

**EXHIBIT INDEX**

31.1	<a href="#">Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2	<a href="#">Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1	<a href="#">Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definitions Linkbase Document

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**STRONGBRIDGE BIOPHARMA PLC**

By:           /s/ A. BRIAN DAVIS            
Name: **A. Brian Davis**  
Title: Chief Financial Officer

Date: July 31, 2019

## CERTIFICATIONS

I, Matthew Pauls, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strongbridge Biopharma plc;
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2019

By: /s/ Matthew Pauls

---

Matthew Pauls  
Chief Executive Officer  
(Principal Executive Officer)

---

## CERTIFICATIONS

I, A. Brian Davis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strongbridge Biopharma plc;
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2019

By:/s/ A. Brian Davis

---

A. Brian Davis  
Chief Executive Officer  
(Principal Executive Officer)

---

## CERTIFICATIONS PURSUANT TO 18 U.S.C. 1350

Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Matthew Pauls, the Chief Executive Officer (principal executive officer) of Strongbridge Biopharma plc (the “Company”), and A. Brian Davis, the Chief Financial Officer (principal financial officer) of the Company, each hereby certifies that, to his knowledge on the date hereof:

(a) The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2019 filed on the date hereof with the Securities and Exchange Commission (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Quarterly Report.

This certification shall not be deemed to be filed with the Securities and Exchange Commission and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

By: /s/ Matthew Pauls

---

Matthew Pauls  
Chief Executive Officer  
(Principal Executive Officer)  
July 31, 2019

By: /s/ A. Brian Davis

---

A. Brian Davis  
Chief Financial Officer  
(Principal Financial Officer)  
July 31, 2019

---

